Ventilator-associated Pneumonia Clinical Trial
Official title:
Prevention of Early Ventilator-associated Pneumonia With Antibiotic Therapy in Patients Treated With Mild Therapeutic Hypothermia After Cardiac Arrest.
Mild therapeutic hypothermia is currently recommended in management of cardiac arrests with
shockable rhythm. In mechanically ventilated patients who were resuscitated after
out-of-hospital cardiac arrests, mild therapeutic hypothermia side effects are conductive for
infectious complications and especially for ventilator-associated pneumonia (VAP).
Despite high incidence of VAP and other infectious complications, it is not currently
recommended to use antibiotic prophylaxis on the responsible germs. Yet VAP incidence could
be decreased if an antibiotic therapy was systematically given to patient treated with mild
therapeutic hypothermia after a cardiac arrest. Several retrospective studies showed less
infectious complications but also decreased morbidity and mortality related to these
complications when antibiotic therapy was given early to patients treated with therapeutic
hypothermia after cardiac arrest.
Multicenter add-on randomized controlled double-blind trial assessing the efficacy of preventive antibiotics amoxicillin-clavulanic acid vs placebo to prevent occurrence of early VAP after out-of-hospital cardiac arrest receiving mild therapeutic hypothermia, in addition to usual VAP prevention measures. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01406951 -
Diagnostic Value of sTREM-1 and PCT Level as Well as CPIS Score for Ventilator-Associated Pneumonia Among ICU Sepsis Patients
|
N/A | |
Completed |
NCT00893763 -
Strategies To Prevent Pneumonia 2 (SToPP2)
|
Phase 2 | |
Recruiting |
NCT03581370 -
Short Infusion Versus Prolonged Infusion of Ceftolozane-tazobactam Among Patients With Ventilator Associated-pneumonia
|
Phase 3 | |
Completed |
NCT02070757 -
Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)
|
Phase 3 | |
Completed |
NCT03348579 -
Hospital-acquired Pneumonia in Intensive Care Unit
|
||
Completed |
NCT04242706 -
VITAL - VAP Prevention by BIP (Bactiguard Infection Protection) ETT Evac in Belgian ICUs
|
Phase 4 | |
Recruiting |
NCT05589727 -
Application of Ventilator-Associated Events (VAE) in Ventilator-Associated Pneumonia (VAP) Notified in Brazil
|
||
Not yet recruiting |
NCT06168734 -
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP
|
Phase 3 | |
Completed |
NCT02515448 -
A Pharmacokinetic-pharmacodynamic Dose Comparison Study of 8 mg/kg of Inhaled or Parenteral Gentamicin in 12 Mechanically Ventilated Critically Ill Patients Treated for Ventilator-associated Pneumonia
|
Phase 1 | |
Completed |
NCT01972425 -
Biomarker-based Exclusion of VAP for Improved Antibiotic Stewardship
|
N/A | |
Completed |
NCT02838160 -
Effectiveness of Different Educational Strategies on the KAP, Psychological and Clinical Outcomes
|
N/A | |
Completed |
NCT01467648 -
The Pharmacodynamics of Doripenem Between 4-hour and 1-hour Infusion in Patients With Ventilator-associated Pneumonia
|
Phase 4 | |
Completed |
NCT00364299 -
Prevention of Ventilator-Associated Pneumonia by Automatic Control of the Tracheal Tube Cuff Pressure
|
N/A | |
Not yet recruiting |
NCT03018431 -
CT Scan and Lung Ultrasonography to Improve Diagnostic of Ventilation Acquired Pneumonia in ICU
|
N/A | |
Completed |
NCT02515617 -
Medico-economic Study of the Subglottic Secretions Drainage in Prevention of Ventilator-associated Pneumonia (DEMETER)
|
N/A | |
Completed |
NCT02585180 -
Subglottic Secretions Surveillance to Predict Bacterial Pathogens Involved in Ventilator-associated Pneumonia
|
N/A | |
Completed |
NCT02583308 -
Impact of the Subglottic Secretions Drainage on the Tracheal Secretions Colonisation
|
N/A | |
Recruiting |
NCT01546974 -
Ventilator-associated Pneumonia (VAP) and Humidification System
|
Phase 4 | |
Completed |
NCT02060045 -
Prevention Ventilator Associated Pneumonia
|
N/A | |
Terminated |
NCT00543608 -
Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia
|
Phase 2 |